These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35355931)

  • 1. A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
    Ying Z; He T; Jin S; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Liu W; Deng L; Ding Y; Hu X; Bu B; Lu X; Song Y; Zhu J
    Chin J Cancer Res; 2022 Feb; 34(1):53-62. PubMed ID: 35355931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
    Zhang Y; Patel RP; Kim KH; Cho H; Jo JC; Jeong SH; Oh SY; Choi YS; Kim SH; Lee JH; Angelos M; Guruprasad P; Cohen I; Ugwuanyi O; Lee YG; Pajarillo R; Cho JH; Carturan A; Paruzzo L; Ghilardi G; Wang M; Kim S; Kim SM; Lee HJ; Park JH; Cui L; Lee TB; Hwang IS; Lee YH; Lee YJ; Porazzi P; Liu D; Lee Y; Kim JH; Lee JS; Yoon DH; Chung J; Ruella M
    Mol Cancer; 2023 Dec; 22(1):200. PubMed ID: 38066564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
    Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
    Front Oncol; 2021; 11():664421. PubMed ID: 34113569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
    Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Qi F; Ding Y; Lu XA; Song Y; Zhu J
    Mol Ther Oncolytics; 2019 Dec; 15():60-68. PubMed ID: 31650026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
    Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
    Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
    Front Oncol; 2019; 9():767. PubMed ID: 31482064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma.
    Zhang Y; Geng H; Zeng L; Li J; Yang Q; Jia S; Zong X; Cai W; Liu S; Lu Y; Yu L; Li C; Wu D
    Hematol Oncol; 2024 Jan; 42(1):e3227. PubMed ID: 37776326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
    Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
    Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
    [No Abstract]   [Full Text] [Related]  

  • 15. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.
    Bao F; Wan W; He T; Qi F; Liu G; Hu K; Lu XA; Yang P; Dong F; Wang J; Jing H
    Cancer Gene Ther; 2019 Jul; 26(7-8):248-255. PubMed ID: 30622321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.
    Zhao X; Yang J; Zhang X; Lu XA; Xiong M; Zhang J; Zhou X; Qi F; He T; Ding Y; Hu X; De Smet F; Lu P; Huang X
    Mol Ther Oncolytics; 2020 Sep; 18():272-281. PubMed ID: 32728615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.
    Yang C; Lei W; Xie H; Wu G; Wei J; Liang A; Qian W
    Onco Targets Ther; 2020; 13():12163-12168. PubMed ID: 33268994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Ying Z; Song Y; Zhu J
    Front Pharmacol; 2022; 13():834113. PubMed ID: 35548364
    [No Abstract]   [Full Text] [Related]  

  • 19. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
    Larson SM; Walthers CM; Ji B; Ghafouri SN; Naparstek J; Trent J; Chen JM; Roshandell M; Harris C; Khericha M; Schweppe T; Berent-Maoz B; Gosliner SB; Almaktari A; Ceja MA; Allen-Auerbach MS; Said J; Nawaly K; Mead M; de Vos S; Young PA; Oliai C; Schiller GJ; Timmerman JM; Ribas A; Chen YY
    Cancer Discov; 2023 Mar; 13(3):580-597. PubMed ID: 36416874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.